5 – MS Relapses During Natalizumab Therapy Traced to Drug’s Greater Impact on Regulatory T-cells
Natalizumab (Tysabri) harnesses multiple sclerosis (MS) activity by targeting CD49, a molecule on the surface of immune cells. Now, researchers found that the drug reduces the factor on regulatory T-cells to a greater extent than on inflammatory T-cells — a mechanism that might explain disease exacerbation during treatment.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?